• A transmembrane glycoprotein, EGFR isa member ofthe tyrosine kinase superfamily of receptors. Literature precedentsindicate that many EGFR gene alterations were found to be involvedin GBM, including amplifications, deletions, and single nucleotidepolymorphisms (SNPs). Detected in 40–60% of GBM cases, EGFRamplifications are generally indicative of poor prognosis. In lightof the aforementioned, monoclonal antibodies directed against wild-typeEGFR and EGFR along with numerous small-molecule tyrosine kinase inhibitorshave been extensively studied in GBM.227. This evidence concerns the gene EGFR and glioblastoma.